GOUT TREATMENT
 

Non-pharmacologic therapy includes lifestyle and dietary changes such as weight management, reduced alcohol intake and consumption of high purine foods (ex. anchovies, asparagus, game meats, gravy, herring, liver, mackerel, mushrooms, sardines, scallops), as well as maintenance of blood pressure and lipid control.

Generic Brand Form(s) Strength(s) Usual Dosage Notes
Acute Attack
Indomethacin Indocin
(Merck)
Caps 25mg
50mg

• 50mg 3 times daily until pain relief; rapidly taper and discontinue

• Use lowest effective dose and shortest duration

• Discontinue if experiencing severe side effects

Supp 50mg
Indocin Susp
(Iroko)
Susp 25mg/5mL
Naproxen Naprosyn
(Roche)
Tabs 250mg (scored)
375mg
500mg (scored)

• 750mg followed by 250mg every 8 hours until pain relief

• EC-Naprosyn not recommended

• Use lowest effective dose and duration

Susp 125mg/5mL
Anaprox
(Roche)
Tabs 275mg

• 825mg followed by 275mg every 8 hours until pain relief

 
Sulindac Clinoril
(Merck)
Tabs 150mg
200mg (scored)

• 200mg twice daily until pain relief; usual duration 7 days

• Use lowest effective dose and shortest duration

• Take with food

• Max dose: 400mg per day

Colchicine Colcrys
(URL Pharma)
Tabs 0.6mg

• Gout treatment: 1.2mg at first sign of gout flare, then 0.6mg 1 hour later; max 1.8mg over a 1 hour period; may be given during prophylaxis at max 1.2mg at first sign of flare, then 0.6mg 1 hour later, wait 12 hours, then resume prophylactic dose. Concomitant CYP3A4 and/or P-glycoprotein inhibitors, severe renal or hepatic impairment: reduce dose (see literature).

 
Prednisone Prednisone
(various)
Tabs (scored) 1mg
2.5mg
5mg
10mg
20mg
50mg

• Individualize dose. Usually 5–60mg daily until pain relief; gradually taper

 
Soln 5mg/5mL  
Intensol 5mg/mL  
Methylprednisolone Depo-Medrol
(Pfizer)
Susp for inj 20mg/mL
40mg/mL
80mg/mL

• IA: Small joint: 4–10mg; medium joint: 10–40mg; large joint: 20–80mg

• Gently move joint after IA inj to aid mixing of susp with synovial fluid

Chronic/Management/Prevention
Allopurinol Zyloprim
(Prometheus)
Tabs (scored) 100mg
300mg

• Initial: 100mg daily. Increase by increments of 100mg daily at weekly intervals until serum uric acid level ≤6mg/dL (minimizes flare-ups)

• Mild: 200–300mg per day

• Severe: 400–600mg per day

• Take with food

• Ensure adequate fluid intake to yield ≥2 liters daily urine output

• Maintain alkaline or neutral urine

• Administer in divided doses

• Max dose: 800mg per day and 300mg per dose

• Discontinue if rash appears

Colchicine Colcrys
(URL Pharma)
Tabs 0.6mg

• Gout prophylaxis: >16yrs: 0.6mg once or twice daily; max 1.2mg/day. Concomitant CYP3A4 and/or P-glycoprotein inhibitors, severe renal or hepatic impairment: reduce dose (see literature).

 
Febuxostat Uloric
(Takeda)
Tabs 40mg
80mg

• ≥18yrs: initially 40mg once daily; if serum uric acid is not <6mg/dL after 2 weeks, may increase to 80mg once daily.

• Gout flare prophylaxis, with an NSAID or colchicine, upon initiation of therapy and for up to 6 months, is recommended.

Pegloticase Krystexxa
(Savient)
Soln for IV infusion after dilution 8mg/mL

• 8mg once every 2 weeks

• Give by IV infusion over at least 2 hours and premedicate with antihistamines and corticosteroids

• Slow rate, or stop and restart at lower rate, if infusion reaction occurs; observe at least 1 hour post-infusion

Probenecid Probenecid
(various)
Tabs (scored) 500mg

• Initial: 250mg twice daily for 1 week

• Maintenance: 500mg twice daily

• Take with plenty of fluids

• Maintain alkaline or neutral urine

• Reduce dose if GI intolerance occurs

Probenecid + Colchicine Probenecid + Colchicine
(various)
Tabs (scored) Probenecid: 500mg
Colchicine: 0.5mg

• Initial: 1 tablet daily for 1 week

• Maintenance: 1 tablet twice daily

• Take with plenty of fluids

• Maintain alkaline or neutral urine

• Reduce dose if GI intolerance occurs

NOTES

KEY: Caps = capsules; IA = intra-articular; IM = intramuscular; Inj = injection; IV = intravenous; SC = subcutaneous; Soln = solution; Susp = suspension; Supp = suppositories; Tabs = tablets

Adapted from: National Institute of Arthritis and Musculoskeletal and Skin Diseases. 2002 [updated 2006]. National Institutes of Health (www.niams.nih.gov)

(Rev. 6/2011)